Fitch Raises Boston Scientific's Rating Outlook to Positive

NATICK, Mass., May 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation
(NYSE: BSX) today announced that Fitch Ratings has raised the Company's rating
outlook to positive from stable, while affirming the Company's corporate
credit rating at BB+.

Fitch said the revised rating outlook reflects:

-- The success the Company has had in stabilizing its drug-eluting stent
(DES) business and returning its cardiac rhythm management (CRM)
business to growth, which has included the launch of a number of new
DES
and CRM products. Fitch noted that the Company's other businesses
have been performing well.

-- The Company's restructuring program, which is nearly completed and
is expected to provide a lower cost structure going forward.

-- The Company's paying down approximately $1.3 billion in debt during
the last four quarters.

-- The Company's research and development efforts, which are expected
to provide a relatively steady stream of new product introductions
across Boston Scientific's entire business.

"The Fitch upgrade is further testimony to the progress we are making in
strengthening our financial fundamentals and driving profitable sales growth,"
said Sam Leno, Executive Vice President and Chief Financial Officer of Boston
Scientific. "It comes as additional welcome news after the March upgrades
from Moody's and Standard and Poor's. We will continue working to improve our
profit margins, free cash flow, debt repayment and financial discipline."

About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These
forward-looking statements are based on our beliefs, assumptions and estimates
using information available to us at the time and are not intended to be
guarantees of future events or performance. These forward-looking statements
include, among other things, statements regarding our financial position and
discipline, new product introductions, debt repayment and cost-savings
initiatives, our growth strategy, and our market position. If our underlying
assumptions turn out to be incorrect, or if certain risks or uncertainties
materialize, actual results could vary materially from the expectations and
projections expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together with other
factors) could affect our ability to implement our business strategy and may
cause actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers are
cautioned not to place undue reliance on any of our forward-looking
statements.

Factors that may cause such differences include, among other things: future
economic, competitive, reimbursement and regulatory conditions; new product
introductions; demographic trends; intellectual property; litigation;
financial market conditions; and, future business decisions made by us and our
competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A - Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file thereafter. We
disclaim any intention or obligation to publicly update or revise any
forward-looking statements to reflect any change in our expectations or in
events, conditions, or circumstances on which those expectations may be based,
or that may affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation

SOURCE Boston Scientific Corporation

Paul Donovan, Media Relations, +1-508-650-8541 (office), +1-508-667-5165
(mobile), or Larry Neumann, Investor Relations, +1-508-650-8696 (office), both
of Boston Scientific Corporation